ArticleMedicine2025
Investigating the prognostic potential of PTPN11 gene in papillary thyroid carcinoma: A comprehensive study of bulk and single cell transcriptome.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
PTPN11 is closely associated with cancer progression. This study aimed to explore its prognostic potential in papillary thyroid carcinoma (PTC) and identify additional PTPN11-related prognostic genes, thereby providing novel insights for PTC treatment. Bulk and single-cell transcriptomic data from public databases were utilized to perform pan-cancer analysis for mining the oncogenic potential of PTPN11, accompanied by functional enrichment, immune infiltration, and drug molecular docking analyses. Univariate Cox regression and least absolute shrinkage and selection operator analyses were employed to screen prognostic genes and construct a risk model. Finally, single-cell level analysis was conducted to identify PTPN11-related key cells and their communication patterns. Pan-cancer analysis revealed that PTPN11 expression levels (high vs low) were significantly correlated with survival differences in PTC and other cancers (P < .05). PTPN11 was enriched in the ribosome and oxidative phosphorylation pathways and negatively correlated with CD56 bright natural killer cells (cor = -0.35, P < .05). It exhibited strong binding affinities with VX-11e, irinotecan, and dactinomycin. Eight prognostic genes (ATP2C2, OPRK1, CLSTN2, AGRP, MMP8, B3GNT4, KCNMB2, and DACT2) were screened out, and a robust risk model was established. Endothelial cells were identified as key cells; the occurrence of PTC reduced their quantity and affected the frequency/intensity of their interactions with mast cells. In conclusion, PTPN11 holds promise as a prognostic marker for PTC and is of great value for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.